type 2 diabetes mellitus
Conditions
Interventions
In both groups, we stop the treatment of DPP-4i or GLP-1 receptor agonists if the patients are treated with them, but we continue the treatment with other antidiabetic drugs. Only this group, No ph
Sponsors
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology
Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Out-patients with type 2 diabetes whose HbA1c is more than 6.5% and less than 15% and who has no changes of diabetic treatment (e.g. diet therapy, exercise cure, medication) within the past 12 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients who has renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose transition (standard deviation and MAGE) by CGM, average blood glucose level, Diabetes Treatment Satisfaction: DTSQ | — |
Secondary
| Measure | Time frame |
|---|---|
| glycoalbumin, the total time that blood glucose level monitored by CGM is less than 70mg/dL, body weight, systolic pressure, diastolic pressure, urine albumin creatinine ratio, C-peptide. | — |
Countries
Japan
Contacts
Public ContactTakahiro Tosaki
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology Diabetes and Endocrinology
Outcome results
None listed